跳至主要内容
临床试验/EUCTR2008-002741-23-DE
EUCTR2008-002741-23-DE进行中(未招募)不适用

Intra-individual, randomized comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in imaging the distal lower limb of patients with known or suspicion of osteomyelitis, evaluated in a blinded read

Berufsgenossenschaftliche Universitätsklinik Bergmannsheil GmbH0 个研究点目标入组 50 人开始时间: 2008年5月30日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • (Diabetic) patients with diagnosis or suspicion of having osteomyelitis, indicated for contrast enhanced MRI
  • Patients who are willing to undergo study procedures
  • Patients who are willing and able to sign informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Patients who have previously entered this study
  • Patients who are in pregnancy or nursery. In women with child bearing potential a pregnancy test must be performed directly before each MR examination in order to safely exclude pregnancy.
  • Patients with any physical or mental status that interferes with the signing of informed consent
  • Patients with a contraindication for MRI
  • Patients who have received any contrast material within 12 hours prior to injection with study, comparator or similar drug in combination with moderate or severe renal impairment.
  • Patients who require emergency treatment
  • Patients with severely impaired hepatic function (e.g. SGPT ? 2 times the upper limit of reference range)
  • Patients with impaired renal function of CKD stadium 3 and higher (e.g. creatinine clearance < 60ml/ min). In patients with known renal impairment, clearance will be calculated based on serum creatinine level using the Cockroft-Gault formula. Calculation of the clearance must be done before begin of study. Serum creatinine value must not be older than one week (7 days) before study related contrast injection.
  • Patients with underlying disease or concomitant medication which may interfere with efficacy evaluation
  • Patients with known anaphylactoid or anaphylactic reaction to any contrast media.

研究者

发起方
Berufsgenossenschaftliche Universitätsklinik Bergmannsheil GmbH

相似试验

进行中(未招募)
不适用
Intra-individual, randomized comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem when imaging the pelvis in patients with spondylarthritides, evaluated in a blinded readPolyarthritisMedDRA version: 9.1Level: LLTClassification code 10046107Term: Unspecified polyarthropathy or polyarthritis involving pelvic region and thigh
EUCTR2007-004222-24-DEDekan des FB Medizin der Johann-Wolfgang Goethe-Universität60
进行中(未招募)
不适用
Intra-individual, randomized comparison of the MRI contrast agents Gadovist® 1.0 versus Prohance® in patients with primary and secondary brain tumors, evaluated in a blinded read
EUCTR2007-002888-27-DEKnappschaftskrankenhaus Bochum
进行中(未招募)
1 期
Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging - Gadovist in breast MRIBreast tumor
EUCTR2009-013432-20-DECharité Campus Mitte52
进行中(未招募)
1 期
Comparison of 2 contrast agents for Magnetic Resonance Imaging in patients with liver cancerPatients with liver cirrhosis and diagnosis of hepatocellular carcinoma based on noninvasive HCC diagnostic (EASL) criteriaMedDRA version: 18.1Level: LLTClassification code 10024667Term: Liver cirrhosisSystem Organ Class: 100000004871MedDRA version: 18.1Level: LLTClassification code 10049010Term: Carcinoma hepatocellularSystem Organ Class: 100000004864
EUCTR2013-002409-75-DECharite30
进行中(未招募)
不适用
Exploratory study to evaluate different MRI-contrast-agent-application-schemes using Gadovist to optimize contrast enhancement for longer lasting breast examination - Contrast agent application schemePatients with recent diagnosis of breast cancer, histologically proven.MedDRA version: 12.1Level: LLTClassification code 10006187Term: Breast cancer
EUCTR2010-018862-22-DEKliniken Essen-Mitte50